Valeant To Acquire Salix Pharmaceuticals
TORONTO – Valeant (Pharmaceuticals International, Inc. (TSX: VRX) is taking over Salix Pharmaceuticals, Ltd.
The Quebec-based company is acquiring all common shares of the North Carolina firm in a deal valued at $14.5 billion.
The boards of both companies have approved the deal that was announced Sunday.
Salix is considered a leader in the American gastrointestinal market.
Valeant chairman and chief executive J. Michael Pearson says Salix is an ideal fit for his company’s portfolio of specialty products.
Valeant is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products, primarily in the areas of dermatology, eye health, neurology and branded generics.
News from © The Canadian Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.
Join the Conversation!
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.
